B. subtilis

Phase 1Small molecule

JJinling Hospital, China

B. subtilis is one of 35 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Irritable Bowel SyndromeActive, not recruiting

Irritable Bowel SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

185 competitors in Irritable Bowel Syndrome

#DrugCompanyPhaseTrials

Lialda

Takeda

Phase 3

2 2

Xifaxan

SSalix

Phase 3

10 3

Zofran

Novartis

Phase 3

1 4

Amitiza

SSucampo Pharma Americas, LLC

Phase 3

5 5

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 6

Zarontin

PParkedale

Phase 3

1 7

Mesalazine

Ferring

Phase 3

4 8

Saccharomyces Boulardii

BBiocodex

Phase 3

3 9

Trulance

SSalix

Phase 3

4 10

Lotronex

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome1 trial

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

Recruiting·JJinling Hospital, China·Phase 1·NCT06612411·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for B. subtilis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B. subtilis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B. subtilis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinling Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJinling Hospital, China

B. subtilis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Irritable Bowel Syndrome1 trial

References

Drug Info

Quick Facts

Related News